San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
ATLANTA, Jan. 29, 2016 -- Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) (the “Company”), a biopharmaceutical company focused on the discovery and development of direct-acting antivirals that address infections that have limited therapeutic options, announced today that management will host a conference call on Friday, February 5, 2016 at 9:00 a.m. ET to review the Company’s financial results for the three month period ended December 31, 2015 and provide an update on recent corporate developments. The Company will issue a press release summarizing its financial results the same day, prior to the conference call.
In order to participate in the conference call, please dial (877) 312-5422 (domestic) or (253) 237-1122 (international) and refer to conference ID number 31712361. The live webcast can be accessed under the Investors section of the Company’s website at www.biotapharma.com or you may use the link:
http://edge.media-server.com/m/p/pa9bmsp5.
About Biota Pharmaceuticals, Inc.
Biota Pharmaceuticals is focused on the discovery and development of direct-acting antivirals to treat infections that have limited therapeutic options and affect a significant number of patients globally. The Company has three product candidates in active clinical development: These include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics currently being evaluated in the Company’s ongoing Phase 2b SPIRITUS trial; BTA585, an oral fusion protein inhibitor in Phase 1 development for the treatment and prevention of respiratory syncytial virus (RSV) infections; and BTA074, a topical antiviral treatment in Phase 2 development for condyloma caused by human papillomavirus types 6 & 11. For additional information about the Company, please visit www.biotapharma.com.
Contact: Mark Colonnese Executive Vice President and Chief Financial Officer Biota Pharmaceuticals, Inc. (678) 221-3381 [email protected] Beth DelGiacco Stern Investor Relations, Inc. (212) 362-1200 [email protected]
